Double-Drug attack on cholesterol: could two be better than one?
NCT ID NCT07581808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether combining two different cholesterol-lowering drugs (inclisiran and alirocumab) works better than using either alone. About 60 adults with high heart risk who cannot take statins will be assigned to one of three groups. The goal is to see if the combo lowers 'bad' cholesterol more effectively and safely over 9 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Centre Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame high cholesterol?
- Can a drop of blood predict disease years before it strikes?
- Ancient herbal mix put to the test against high cholesterol
- Cookies that could fight cholesterol: pumpkin seeds and walnuts put to the test
- Could a daily pill help kids with inherited high cholesterol?
- Free meds and tailored education may cut heart risks in Low-Income seniors